Molecular Formula | C26H25F2N3O6
|
Molar Mass | 513.49 |
Density | 1.346±0.06 g/cm3 (20 ºC 760 Torr) |
Boling Point | 808.9±65.0 °C(Predicted) |
Solubility | DMSO: 25 mg/mLEthanol: 100 mg/mL (194.75 mM)( < 1 mg/ml refers to the product slightly soluble or insoluble) |
Appearance | powder |
Color | white to light brown |
pKa | 3.92±0.19(Predicted) |
Storage Condition | -20°C |
Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month. |
Use | Q-VD-OPh is an irreversible pan-caspase (caspase) inhibitor with high anti-apoptotic ability. The IC50 value of inhibiting caspase 7 is 48 nM, and the IC50 value of inhibiting caspase 1,3,8,9,10,12 is between 25 and 400 nM. Q-VD-OPh can inhibit HIV infection. Q-VD-OPh can penetrate the blood-brain barrier. |
Target | Caspase-1; Caspase-3; Caspase-8; Caspase-9 |
In vitro study | Q-VD-OPh (5-100 μm) effectively inhibited the DNA gradient induced by Actinomycin D and the subsequent apoptosis in WEHI 231 cells with little cytotoxicity. Q-VD-OPh prevented caspase-mediated PARP cleavage and activation of the major promoter and effector caspase. Q-VD-OPh protects against Virus-induced cardiomyocyte apoptosis. |
In vivo study | Q-VD-OPh inhibited caspase-1 activity, IL-18 protein expression, and neutrophil infiltration in ischemic mice. In the in vivo test, Q-VD-OPh by inhibiting the activity of caspase-3, to avoid Virus induced myocardial injury. In the TgCRND8 mouse model, Q-VD-OPh inhibited caspase-7 of activation and inhibited tau-related pathological changes. |